Bronchiectasis is a chronic respiratory disorder characterized by persistent productive cough and recurrent chest infections secondary to permanent structural airway damage. The current treatment strategies for this debilitating disorder are limited to prompt antibiotic treatment of infective exacerbations and regular airway clearance techniques. Despite its high morbidity and associated mortality across all age groups, it has been a neglected area of research in respiratory medicine and there remain no licensed disease-modifying therapies. In this review, we have explored the numerous potential therapeutic targets to break the vicious cycle of infection and inflammation seen in these patients and the novel therapeutic agents that have been developed to target them. We have reviewed the role of novel antiinflammatory agents designed to target the persistent neutrophilic inflammatory infiltrate seen in bronchiectatic airways, including neutrophil elastase inhibitors, CXCR2 (CXC chemokine receptor 2) antagonists, DPP-1 (dipeptidyl peptidase 1) inhibitors, PDE4 (phosphodiesterase 4) inhibitors and statins. Furthermore, we have explored novel targets to improve mucociliary clearance, namely ENaC (epithelial sodium channel) inhibitors, and discussed the potential of alternative antimicrobial strategies such as inhaled phages. Our review highlights the importance of a multi-faceted approach to bronchiectasis management, which aims not only to eradicate or suppress bronchial infection but also to break the cycle of persistent airway inflammation that results in progressive lung damage in these patients.
INTRODUCTION
Despite its increasing recognition in adult and paediatric populations, there remain few recommended treatments for bronchiectasis management, and it continues to be recognized as a historically neglected area of research in respiratory medicine. 1, 2 First described by Laennec in 1819, and characterized by a clinical syndrome of productive cough and recurrent lower respiratory tract infections, bronchiectasis is a debilitating, chronic disorder affecting 2-5 per 1000 population. [3] [4] [5] However, this figure is likely to underestimate its true prevalence, as diagnosis requires a high index of suspicion and access to respiratory specialists and highresolution computed tomography (HRCT). It is diagnosed according to radiological criteria whereby bronchoarterial ratio is ≥1.0 in adults and ≥0.8 in children. 6, 7 In clinical practice, it is well recognized, particularly amongst paediatricians, that diagnosis by CT alone has limitations and the term 'chronic suppurative lung disease' is often used to describe patients with consistent clinical symptoms who lack the defining radiological abnormalities. 8 Bronchiectasis can be caused by a number of underlying conditions, including immune function disorders, ciliary dyskinesias, allergic bronchopulmonary aspergillosis (ABPA) and inflammatory bowel disease. However, most cases are secondary to severe lower respiratory tract infection such as pneumonia, adenovirus, Bordetella pertussis or tuberculosis, and up to 50% of adult patients have no obvious underlying disorder and are labelled idiopathic. 9, 10 Bronchiectasis often coexists with other respiratory tract disorders such as COPD and severe asthma, and is associated with worse outcomes and poorer treatment response in these patients. [11] [12] [13] [14] Patients not infrequently report symptoms of chest pain, haemoptysis, breathlessness and fatigue, in addition to the complications of chronic productive cough, all of which play a role in their reduced health-related quality of life (HRQoL). [15] [16] [17] These symptoms are proportional to airway bacterial load, which results in significant local and systemic inflammation. [18] [19] [20] [21] While it is most frequently observed in patients aged >60 years, it is prevalent in all age groups and cases now exceed the number of patients with cystic fibrosis (CF)-related bronchiectasis even in paediatric cohorts. [22] [23] [24] The permanent dilatation and airway scarring lead to impairment of the normal mucociliary escalator with resultant pooling of secretions that provides an ideal environment for opportunistic bacterial infection to develop and persist. 25 Pathogens in the lower airway result in recruitment and activation of inflammatory cells, with consequent airway oedema and mucus hypersecretion, often with failure of bacterial eradication, which perpetuates the cycle of infection and inflammation. In the early natural history of the disease, recurrent infections can generally be cleared by prolonged courses of oral antibiotics, but over time this typically progresses to chronic bacterial infection of the lower airways with associated decline in lung function, progressive structural damage and poorer quality of life. 15, 20 Despite this, it has been demonstrated that aggressive management of HRCTdemonstrated bronchial dilatation in children can be reversed or significantly improved in its early stages, highlighting the importance of prompt diagnosis and management, particularly in the developing lung. 26 Currently, the mainstay of bronchiectasis management is early initiation of culture-targeted antibiotic therapy for infective exacerbations and regular airway clearance. 27 Trials of common respiratory medications such as inhaled corticosteroids (ICS), long-acting muscarinic antagonists (LAMA) and long-acting beta agonists (LABA) remain unproven therapies in bronchiectasis due to a lack of randomized controlled trials (RCT) and are not recommended as maintenance therapy unless there is co-morbid obstructive airway disease. [27] [28] [29] [30] Understandably, there has been much focus on the role of suppressive antibiotic therapy in these patients, and there have been numerous trials focusing on the role of long-term macrolides and inhaled antibiotics, which are commonly prescribed offlabel by tertiary care centres. 5, [31] [32] [33] [34] Detailed exploration of these treatments is beyond the scope of this review. Despite this, the evidence base for these treatments remains insufficient with respect to their long-term effects on the airway microbiome, treatment emergent pathogens and development of bacterial resistance and as such none are currently licensed for use in bronchiectasis. Historically, many of the management strategies for bronchiectasis have been extrapolated from trials conducted in CF patients. However, studies demonstrating the detrimental effects of recombinant human DNase (rhDNase) on lung function and exacerbations in non-CF bronchiectasis and more recently exploration of inhaled aztreonam have highlighted that this approach is significantly flawed due to the divergent molecular mechanisms underlying these disorders. [35] [36] [37] The paucity of clinical trials in bronchiectasis in comparison to those of other respiratory disorders such as CF, asthma and COPD has led it to be described as an 'orphan' disease, despite its high prevalence in both developed and developing nations and increasing recognition of the significant morbidity and mortality it causes. In this review article, we will focus on trials of potential therapies currently in development for the future management of bronchiectasis.
TARGETING NEUTROPHILIC INFLAMMATION

Neutrophil elastase inhibitors
Bronchiectatic airways typically contain dense neutrophilic inflammatory infiltrate, yet are paradoxically colonized with bacteria. This failure of effective pathogen eradication and efferocytosis of host and pathogen cellular debris results in release of cytoplasmic histotoxins that drive further lung damage. 38, 39 Across the medical disciplines, there has been much interest in the role of modifying the neutrophil's response to inflammatory insults to disrupt or even halt the process of chronic inflammation in disease, and to limit damage caused to the host by their own defences. Neutrophil elastase (NE) is a wellcharacterized serine protease secreted by neutrophils in response to acute inflammation and has broad substrate specificity for extracellular matrix proteins, allowing for destruction of both foreign and host cells. 40, 41 These potentially deleterious effects play a role in numerous inflammatory disorders, including COPD, CF and bronchiectasis. [42] [43] [44] Whilst totally disarming the neutrophil in the setting of chronic infection would clearly be catastrophic, altering the inflammatory environment towards a pro-resolution phenotype and reducing the damage to tissues inflicted by the host response offers one strategy to break the vicious cycle seen in the bronchiectatic lung.
AZD9668 (tradename Alvelestat) is an experimental compound originally developed by AstraZeneca Pharmaceuticals (Cambridge, UK) that has been shown to be an orally bioavailable, reversible inhibitor of NE that is both safe and tolerable in human subjects. 45, 46 In 2013, Stockley et al. published a phase II RCT of 28 days of AZD9668 60 mg b.d. versus placebo in a double-blind study. 47 Thirty-eight clinically stable patients with idiopathic or post-infective bronchiectasis were randomized to receive treatment (n = 22) or matched placebo (n = 16), and the primary outcome measures of the study were absolute and percentage neutrophil counts in waking and post-waking sputum samples; change from baseline in 24-h sputum weight, change from randomization in pre-bronchodilator forced expiratory volume in 1 s (FEV 1 ), slow vital capacity (SVC), forced vital capacity (FVC) or forced expiratory flow 25-75% (FEF ); BronkoTest card data and HRQoL as assessed via St George's Respiratory Questionnaire (SGRQ; scored 0-100, minimum clinically important difference 4 units). 48 There was no significant difference in waking or post-waking sputum neutrophil counts from baseline between treatment and placebo groups, with mean waking (post-waking) samples demonstrating counts of 5.63 (5.19) versus 5.34 (5.75) × 10 6 /g at baseline versus end of study in the placebo group and 6.57 (6.69) versus 6.5 (7.05) × 10 6 /g in the treatment group. The 24-h sputum weight was reduced in the treated group with a mean decrease of 8.27 g versus an increase of 5.01 g in the placebo group but this did not reach statistical significance (P = 0.367). Increases in all pulmonary function parameters were noted in the treatment versus the placebo arms; however, these only reached statistical significance for FEV 1 and SVC at P = 0.006 and P = 0.079, respectively, which equated to a mean difference of 100 mL in FEV 1 and 130 mL in SVC versus placebo. Sputum NE activity was assessed as a secondary outcome measure and although a trend towards reduced activity was noted in the treatment group, it did not achieve statistical significance. Studies of AZD9668 have been published in COPD and CF and AstraZeneca has recently announced a licensing agreement with Mereo Biopharma, which report a planned phase II proof-of-concept study in patients with severe alpha-1 antitrypsin (α1AT) deficiency. [49] [50] [51] Watz et al. recently published an abstract of a multicentre, phase IIa, double -blind placebo-controlled randomized trial of another NE inhibitor, BAY 85-8501 in 94 patients with bronchiectasis.
52 BAY 85-8501 is a novel, selective and reversible NE inhibitor currently in development by Bayer Healthcare. 53 The primary endpoint was the safety and tolerability of treatment over 4 weeks, with secondary analyses of lung function, biomarkers of inflammation and health status. They reported treatment-emergent adverse events (TEAE) in 31 patients in the treatment and 36 patients in the placebo arms, with no serious TEAE in either group deemed to be related to study treatment. There were no significant changes in lung function or sputum NE activity, concentration or 24-h weight.
Perhaps due to the relatively modest improvements demonstrated by these studies, and the failure to achieve reductions in sputum neutrophil density or 24-h volume, no further trials in bronchiectasis are currently listed. It is perhaps likely that inhaled administration of therapy will be required to achieve sufficient concentrations at the target site to demonstrate clear therapeutic effects.
α1AT replacement
As explored above, the deleterious effects of excess serine proteases have been demonstrated across a plethora of chronic inflammatory lung diseases. An alternative strategy for the reduction of their actions is to alter the balance of proteases versus anti-proteases in the inflamed lung, rather than directly inhibit their actions. Perhaps the best characterized of the host antiproteases is α1AT, which is well known for its role in the development of early onset, severe panlobular emphysema in patients homozygous for the PiZZ allele, which confers a significant loss of α1AT function. 54 The link between α1AT deficiency and bronchiectasis is widely reported. 55, 56 While patients without true deficiency have sufficient circulating levels of this vital anti-protease, it is likely they demonstrate relative deficiency in the inflamed lung due to the relative increase in free serine proteases, thus altering the balance of pro-and anti-inflammatory factors. On this basis, it is possible that α1AT replacement may confer benefits in established neutrophilic inflammatory lung disease due to its ability to alter the inflammatory microenvironment, and has demonstrated efficacy in CF patients. 57 A single trial of inhaled α1AT in stable bronchiectasis patients with chronic sputum production was identified from searches (NCT03383939), and reportedly completed in 1999, but we were unable to identify any published results. With increasing emphasis on the role of altering the balance of pro-inflammatory versus proresolution mediators, inhaled α1AT likely warrants further exploration as a therapeutic agent in this population.
DPP-1 inhibitors
Dipeptidyl peptidase 1 (DPP-1), also known as cathepsin C (CTSC) is a lysosomal protease that activates a variety of serine proteases produced by neutrophils and other inflammatory cells. 58 A novel small molecule, reversible, orally bioavailable inhibitor of DPP-1 known as INS1007 (formerly AZD7896), designed to ameliorate the effects of neutrophil-dependent inflammatory disorders has recently been developed. [59] [60] [61] A multicentre, randomized, double-blind placebo-controlled trial of INS1007 over 24 weeks, the Willow study, is currently recruiting bronchiectasis patients (NCT03218917/ EudraCT 2017-002533-32). The primary outcomes measures are time to first pulmonary exacerbation and safety and tolerability assessments, with secondary exploration of effects on HRQoL, pulmonary function, exacerbation rate and sputum NE.
CXCR2 antagonists
CXC chemokines are members of a large group of lowmolecular weight proteins known to induce leukocyte chemotaxis, and are implicated in the pathogenesis of numerous chronic inflammatory diseases. 62 Their allied receptors, CXCR1 and CXCR2, are expressed on cells implicated in bronchial inflammation including leukocytes, epithelial cells, smooth muscle and vascular endothelium. 63 Neutrophil recruitment to the lung can be triggered via the expression of numerous proinflammatory mediators, including interleukin 8 (IL-8, also known as CXCL8), which is elevated in patients with bronchiectasis. 64, 65 Monoclonal antibodies to IL-8 have been explored as potential treatment agents for established neutrophilic airway disease related to COPD. 66 IL-8 has binding affinity for a variety of surface receptors, including CXCR2, and disrupting this pathway may be of benefit in limiting neutrophilic infiltrate to the lung. In recent decades, a flurry of research into CXC chemokines has led to the discovery of potent and selective CXCR1 and 2 inhibitors, many of which have been developed as therapeutic agents. 63 De Soyza et al. completed a multicentre 28-day RCT of AZD5069, a selective CXCR2 inhibitor, versus placebo in 52 patients with stable idiopathic or postinfective bronchiectasis and a history of chronic sputum production. 67 The primary endpoint of the study was the absolute change in neutrophil cell count of spontaneous 2-h post-waking sputum samples, while secondary endpoints included percentage sputum neutrophil counts, BronkoTest diary card scores and HRQoL as assessed by SGRQ. Absolute sputum counts were significantly decreased (P = 0.004) in the treated group, with ratio of end of treatment to baseline values of 1.044 for placebo versus 0.297 in the AZD5069 group. Serum IL-8 concentrations were increased sixfold (P < 0.001), and there was no evidence of increased infection rate or significant neutropenia in response to treatment. AZD5069 has also been trialled in uncontrolled severe asthma, demonstrating no reduction in severe exacerbations, and moderate-tosevere COPD, where it was well tolerated with no evidence of increased infective exacerbations. 68, 69 Searches have demonstrated active trials in metastatic cancer (NCT03177187) and coronary artery disease, but no further reports of trials in neutrophilic lung disease.
PDE4 inhibitors
Phosphodiesterase (PDE) enzymes, of which 11 subtypes are expressed in mammalian tissues, are responsible for the rapid intracellular degradation of the second messenger cyclic adenosine monophosphate (cAMP).
70 PDE4, which is implicated in the pathogenesis of inflammatory lung conditions, can be further divided into four subtypes (A-D), and blockade of PDE4B is associated with reduced neutrophil chemotaxis, decreased release of pro-inflammatory mediators and induction of neutrophil apoptosis. 71 In addition, it reduces IgE-mediated mast cell degranulation and enhances β2 agonist-induced bronchodilation. 70 Roflumilast, (tradename Daxas, AstraZeneca (Cambridge, UK)), a potent and selective PDE4 inhibitor, is the most extensively investigated of a number of therapeutic PDE4 antagonists, and is approved for use in severe COPD with recurrent exacerbations despite maximal inhaled therapy. 72 Roflumilast has been shown to significantly improve lung function and reduce the severity of exacerbations in patients with severe COPD. 73 Park reported the early results of a phase 2 trial of roflumilast in bronchiectasis in an abstract at the American Thoracic Society conference in 2014. 74 Symptomatic bronchiectasis patients were enrolled to a small single arm trial of 16 weeks duration, in which patients received 250 (n = 4) or 500 μg (n = 5) daily of roflumilast and the primary outcome measures were HRQoL as assessed via the COPD assessment test (CAT) score and SGRQ. Treatment significantly reduced the CAT score from 19.77 AE 5.78 to 9.89 AE 4.01 (P = 0.008) and also reduced the SGRQ score from 26.06 AE 8.42 to 19.46 AE 5.229, but this did not achieve statistical significance (P = 0.066). A new trial of roflumilast (NCT03428334) is currently recruiting patients with stable bronchiectasis in Hong Kong, the primary outcome measure of which is sputum leukocyte density following 4 weeks of treatment.
MODULATING HOST RESPONSE TO INFECTION Oral immunostimulant therapy-OM-85
Chronic airway infection and repeated pulmonary exacerbations are key drivers of disease progression in bronchiectasis. Management of infection with long-term suppressive antibiotics can lead to the development of antibiotic-resistant organisms, which is a potential limitation. There has been increasing interest in the role of immunostimulating agents in the management of chronic bronchial infection as an alternative treatment strategy. OM-85 is an orally bioavailable extract of bacterial antigens from eight different recognized respiratory pathogens. 75 The daily administration of these inactivated bacterial components results in stimulation of cellular and humoral immunities, mediated largely via induction of immunoglobulin synthesis and the stimulation of Th1 cells. 75 OM-85 has been explored as a therapeutic strategy for underlying chronic lung disease and as a preventive tool for the management of recurrent respiratory tract infections in pre-school and school age children. In the paediatric population, it has been shown to reduce the number and duration of respiratory tract infections, the number of missed school days and antibiotic prescriptions in several randomized trials. 76, 77 For a comprehensive exploration of the evidence in this population, we direct the readers to a recent systematic review by Schaad, which concludes that these effects are most marked in children with a known propensity to recurrent infection. 78 In adults, it has been demonstrated to significantly reduce the number of exacerbations and the length of hospital admissions due to respiratory exacerbations in COPD. 79, 80 More recently, an open-label prospective study by Koatz et al. included 84 adults with allergic rhinitis, asthma or COPD and a history of recurrent respiratory tract infections to a 3-month trial of intermittent OM-85 treatment. 81 They demonstrated a significant reduction in the number of respiratory tract infections in the period following treatment versus the year prior, and a reduction in the total number of exacerbations related to the underlying condition versus standard treatment alone.
Gao et al. published a protocol for a RCT of OM-85 in the prevention of bronchiectasis exacerbations (iPROBE) in Chinese patients in 2014 (NCT01968421). 82 The study was reported to be completed in January 2018 and the results are yet to be published.
Vitamin D
Vitamin D is known to exhibit pleiotropic effects on the immune system via modulation of both cytokines and Th cell responses. 83 Deficiency of vitamin D has been linked with increased bacterial colonization and exacerbation frequency, as well as markers of disease severity in patients with bronchiectasis, as is associated with increased risk of upper respiratory tract infection . 84, 85 The question of whether vitamin D deficiency is causally associated with severe disease or is merely secondary to reduced sunlight exposure that may accompany persistent ill health remains unanswered. Research into the effects of vitamin D replacement is fraught with complication due to ongoing debate with respect to its optimum serum concentration and thus the aim of replacement therapy.
Martineau et al. conducted a double-blind RCT of intermittent vitamin D 3 (cholecalciferol) administration in patients with COPD, and found it to protect against moderate-severe exacerbations, although not the development of upper respiratory tract infection, in patients with true vitamin D deficiency (serum concentration < 50 nmol/L). 86 A phase IV trial of vitamin D as an adjunctive treatment for bronchiectasis (NCT02507843) is currently recruiting patients with the primary outcome measure of time to first acute exacerbation over a 1-year follow-up period.
REDUCING SYSTEMIC INFLAMMATION Statins
Patients with bronchiectasis have elevated systemic inflammatory markers such as C-reactive protein (CRP), the levels of which are inversely associated with pulmonary function and HRQoL in stable disease. 87 In addition to this, bronchiectasis is an independent risk factor for cardiovascular disease, likely due to chronic systemic inflammation and hypoxia. 88 HMG-CoA reductase inhibitors, commonly known as statins, are a class of drugs originally developed for their lipidlowering capabilities, which have been discovered to possess immune-modulating, anti-inflammatory properties. 89, 90 Observational studies of community-acquired pneumonia have demonstrated reduced mortality in patients receiving concurrent statin treatment, and in murine models they have been shown to reduce infection-induced neutrophil chemotaxis. 91, 92 Mandal et al. recruited 60 patients with idiopathic or post-infective bronchiectasis and a history of daily sputum production and recurrent exacerbations to a 6-month double-blinded RCT of 80 mg atorvastatin OD versus placebo (lactose). 93 The primary outcome measure was a reduction in cough severity from baseline to 6 months, assessed via the Leicester Cough Questionnaire (LCQ; scored 3-21, minimum clinically important difference 1.3 units), and secondary outcomes included pulmonary function, exercise tolerance, sputum bacteriology, SGRQ scores, sputum neutrophil numbers and apoptosis. 94 At 3 and 6 months, the LCQ scores were significantly increased in the treated patients, with mean difference between the atorvastatin and placebo groups of 3.3 and 2.2 units at 3 and 6 months, respectively (P = 0.006 and P = 0.01). At 6 months, fewer viable and more apoptotic neutrophils were demonstrated in sputum of the treated patients versus baseline, while there was no demonstrable difference in the placebo group.
Following on from this, Bedi et al. went on to conduct a further proof-of-concept study in patients with severe bronchiectasis colonized with Pseudomonas aeruginosa . 95 Thirty-two patients were recruited to this doubleblind, crossover RCT, and received atorvastatin 80 mg OD or placebo for 3 months and following a 6-week washout period were switched to the other arm. As in their first trial, the primary outcome measure was an improvement in cough severity as assessed via LCQ. The mean change in LCQ between treated and placebo patients was 1.92, which was not statistically significant (P = 0.125); however, there was a significant difference in SGRQ scores in the statin-treated group, with a mean difference of −5.62 between the groups (P = 0.016). They also reported a significant reduction in serum IL-8 (CXCL8), TNF and Intracellular Adhesion Molecule 1 (ICAM-1), and a non-significant trend towards reduced serum CRP and serum neutrophil counts in response to statin therapy. Their in vitro experiments highlighted the ability of atorvastatin to reduce neutrophil activation and calcium flux, suggesting that the beneficial effects of statin therapy are likely secondary to the modulation of neutrophil function.
ENHANCING MUCOCILIARY CLEARANCE ENaC inhibition
Failure to clear excessive airway secretions is a hallmark of bronchiectasis and regular airway clearance is a recommended treatment modality that aims to improve mucociliary clearance. Patients with underlying primary ciliary dyskinesia (PCD), a spectrum of genetic disorders in which cilia are absent, immotile or dysmotile, have inherently impaired mucociliary escalators, resulting in recurrent sinopulmonary infections. 96 ENaC is an epithelial sodium channel present on cilia that regulates composition of airway surface liquid via sodium resorption. 97 It is downregulated by functional CFTR (the chloride ion channel mutated in CF, CF transmembrane conductance regulator) and its consequent upregulation in CF patients contributes to the viscous mucus that is pathognomic of the disorder. 98 Downregulation of ENaC is postulated to be a potential therapeutic strategy for reducing mucus viscosity and improving clearance of lower airway secretions, thereby reducing the propensity to develop bacterial infections. VX-371 (formerly P-1037) is a novel inhaled ENaC inhibitor that is being investigated as a potential therapy both alone and as an adjuvant to inhaled hypertonic saline and oral Ivacaftor (a CFTR potentiator). 99 An RCT of these treatments in PCD patients is currently recruiting, with the primary endpoints of improved pulmonary function and safety and tolerability data (NCT02871778).
ERADICATION OF BACTERIAL INFECTION Phage therapy
The major trigger of neutrophilic inflammation in the bronchiectatic lung is persistent bronchial infection, with approximately 70% of patients chronically colonized by potentially pathogenic microorganisms including Haemophilus influenzae, Moraxella catarrhalis, Stenotrophomonas maltophilia and P. aeruginosa. 100, 101 Established chronic infection in the bronchiectatic lung is very difficult to eradicate even when it remains susceptible to available antibiotics, and the use of inhaled antibiotics, which achieve much higher concentrations at the site of infection than can be tolerated via the oral or intravenous route, is an ongoing focus of bronchiectasis research. 102, 103 However, in recent years there has been increasing recognition of the imminent 'post antibiotic era', in which many common pathogens are resistant to antibiotics, and as such there is renewed interest in alternative strategies for combating bacterial infection.
Bacteriophages, naturally occurring bacterial viruses, were first discovered by Twort in 1925, and ever since there have been efforts to deploy them as treatments for human infectious diseases. 104 Phages are highly specific and rapidly bactericidal to individual pathogens but pose no threat to eukaryote cells. Despite early interest, phage technology was largely eschewed by the West in the latter half of the 20th century due to the rapid development of new and effective antimicrobials. Much of the currently available research was conducted in the USSR, likely due to both restricted access to Western medicines and a desire to explore alternative technologies. Much of the evidence is confined to descriptive case series where phages were used in a last-ditch attempt to combat refractory infections, with no robust RCT available. For a more detailed exploration of these, see a recent review by Abedon exploring the history of phage therapy and its current evidence base. 105 Most studies to date have employed 'phage cocktails', which contain a variety of phages active against different bacterial species. A recent research letter by Waters et al. highlighted the potential of inhaled phages by demonstrating the effects of their administration on a murine model of chronic lung infection with an epidemic strain of P. aeruginosa. 106 They report a significant reduction in bacterial Colony Forming Units (CFU) from lung homogenate when phage was administered intranasally at a variety of time points ranging from 24 to 156 h post-infection. Several studies have reported the in vitro activity of phages against P. aeruginosa in biofilms isolated from the sputum of infected CF patients, where multidrug-resistant P. aeruginosa represents an increasing clinical problem. It is possible that phages will ultimately prove a useful adjuvant to topical or systemic antibiotic therapy, with which they have demonstrated synergistic effects in several reports.
CONCLUSIONS
Despite the current paucity of licensed diseasemodifying treatments in bronchiectasis, this review highlights the broad range of therapeutic targets that could be exploited in the search for new therapies. See Table 1 for a summary of key findings of the completed clinical trials we have discussed above. Figure 1 provides a diagrammatic representation of the site of action of the potential therapies we have discussed and highlights the importance of a multi-faceted approach to the management of bronchiectasis. Breaking the Bronchiectasis: Emerging therapies vicious cycle of infection and inflammation early in the disease course is likely to hold the key to improved outcomes in the longer term for this challenging group of patients. As our understanding of the mechanisms of initiation and persistence of inflammation increase, it is likely that further drug targets will be elucidated. Modulating the inflammatory cascade is challenging due to its multi-faceted nature, and ultimately it is likely that a combination of agents targeting different points in the cascade will be required to produce meaningful clinical changes. Blockade of these pathways at their higher levels and the resultant excessive downregulation of the innate inflammatory response run the risk of inadvertent immune suppression with potentially catastrophic adverse effects. Furthermore, the presence of active bacterial infection, as seen in the bronchiectatic lung, represents a potent immune stimulant, and it is unlikely that even highly efficacious anti-inflammatory therapies will be able to completely overcome this if they are not deployed in combination with antimicrobial treatment. It remains unclear where in the disease course anti-inflammatory therapies would offer the most efficacy, and whether they should be used alone or as adjuncts to long-term antimicrobials. The development of novel antibiotics is fraught with difficulty, and as such alternative treatments such as topical delivery of currently available agents, or novel strategies such as phage therapy require further exploration and robust clinical assessment.
In the new dawn of bronchiectasis research, we have seen an increase in the number of trials designed specifically to target affected patients and improved recognition of bronchiectasis as a pathophysiologically distinct disease entity. The number of patients with bronchiectasis significantly exceeds that of those with CF across all age groups, yet the number of studies remains low in comparison to those for CF. Although bronchiectasis shares many pathological features with other lung diseases including CF, COPD and neutrophilic asthma, it is critical that treatment strategies employed in these groups are tested via robust clinical trials rather than extrapolated blindly.
Early aggressive management of bronchial dilatation in children can lead to reversal or amelioration of lung damage, and it is possible that the same is true for adults with early disease. As such, it is reasonable to postulate that effective anti-inflammatory therapies may reverse damage in the inflamed lung and prevent descent into the vicious cycle that is the hallmark of established disease, thus preventing or delaying permanent airway scarring. Although the challenges of developing safe and effective anti-inflammatory and antimicrobial treatments are many and varied, there remains hope for the future of bronchiectasis management.
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